TP53 and neoplasm: Voorhoeve et al. first pinpointed miR-372 and miR-373 as oncogenic markers in TGCTs, demonstrating their role in the downregulation of the p53 pathway, allowing tumor growth and proliferation in the presence of wild-type TP53 [70].